KaliVir Immunotherapeutics, Inc., a clinical-stage biotechnology company developing cutting-edge, multi-mechanistic oncolytic immunotherapy programs, today announced the upcoming presentation of a ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Some health professionals already recommend the DASH diet (Dietary Approaches to Stop Hypertension) for patients with high ...

Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...

The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...

First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced ovarian cancer Initiation ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Aulostm Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today announced the presentation of new data ...

Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...

Surrozen said despite SZN-043 demonstrating changes in liver function assays, there was not enough clinical benefit for ...